Automatically Identifying Drug Conflicts in Clinical Practice Guidelines

Clinical Practice Guidelines (CPGs) are documents developed in a systematic way that aim to improve the quality of health care, reduce variations in medical practice, and reduce health care costs. However, when concurrently apply them, this can lead to adverse drug-drug interactions that can impair the patient’s condition. Several efforts have been made in order to provide systems capable of identifying these conflicts. However, the current approaches for this purpose have some limitations. This paper presents a solution that represents CPGs as Computer-Interpretable Guidelines (CIGs) and allows for the automatic drug conflict identification and resolution. Also, we provide the identification of improvements to include in a future model. Moreover, this system provides clinical recommendations in an agenda, being capable of identifying drug interactions when drugs are prescribed simultaneously and provide conflict-free alternatives.

[1]  Wei Ma,et al.  RxNorm: prescription for electronic drug information exchange , 2005, IT Professional.

[2]  B. Guthrie,et al.  Drug-disease and drug-drug interactions: systematic examination of recommendations in 12 UK national clinical guidelines , 2015, BMJ : British Medical Journal.

[3]  Katharina Kaiser,et al.  Computer-interpretable Guideline Formalisms , 2008, Computer-based Medical Guidelines and Protocols.

[4]  Yuval Shahar,et al.  Synthesis of Research: EON: A Component-Based Approach to Automation of Protocol-Directed Therapy , 1996, J. Am. Medical Informatics Assoc..

[5]  P. Aschner,et al.  New IDF clinical practice recommendations for managing type 2 diabetes in primary care. , 2017, Diabetes research and clinical practice.

[6]  W. Michalowski,et al.  Reconciling pairs of concurrently used clinical practice guidelines using Constraint Logic Programming. , 2011, AMIA ... Annual Symposium proceedings. AMIA Symposium.

[7]  A. Wu,et al.  Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. , 2005, JAMA.

[8]  Matthias Samwald,et al.  The Arden Syntax standard for clinical decision support: Experiences and directions , 2012, J. Biomed. Informatics.

[9]  José Neves,et al.  Representation of Clinical Practice Guideline Components in OWL , 2013, PAAMS.

[10]  M. Tinetti,et al.  Potential pitfalls of disease-specific guidelines for patients with multiple conditions. , 2004, The New England journal of medicine.

[11]  José Neves,et al.  A System for the Management of Clinical Tasks Throughout the Clinical Process with Notification Features , 2017, A2HC@AAMAS/A-HEALTH@PAAMS.

[12]  jafarpour borna,et al.  ONTOLOGY MERGING USING SEMANTICALLY-DEFINED MERGE CRITERIA AND OWL REASONING SERVICES: TOWARDS EXECUTION-TIME MERGING OF MULTIPLE CLINICAL WORKFLOWS TO HANDLE COMORBIDITIES , 2014 .

[13]  Frank van Harmelen,et al.  Inferring recommendation interactions in clinical guidelines , 2016, Semantic Web.

[14]  Omolola Ogunyemi,et al.  GLIF3: the evolution of a guideline representation format , 2000, AMIA.

[15]  Maarten J. IJzerman,et al.  Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  David Riaño,et al.  Rule-Based Combination of Comorbid Treatments for Chronic Diseases Applied to Hypertension, Diabetes Mellitus and Heart Failure , 2012, ProHealth/KR4HC.

[17]  Syed Sibte Raza Abidi,et al.  Merging Disease-Specific Clinical Guidelines to Handle Comorbidities in a Clinical Decision Support Setting , 2013, AIME.

[18]  José Neves,et al.  CompGuide: Acquisition and Editing of Computer-Interpretable Guidelines , 2017, WorldCIST.

[19]  NevesJosé,et al.  Decision Support Provided by a Temporally Oriented Health Care Assistant , 2017 .

[20]  Alessio Bottrighi,et al.  Clinical Guidelines Contextualization in GLARE , 2006, AMIA.

[21]  Tara McLaughlin,et al.  National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer—Is Active Surveillance Appropriate? , 2017, The Journal of urology.